CN1233645C - 新的东罂粟碱衍生物及其医药用途 - Google Patents
新的东罂粟碱衍生物及其医药用途 Download PDFInfo
- Publication number
- CN1233645C CN1233645C CNB011421495A CN01142149A CN1233645C CN 1233645 C CN1233645 C CN 1233645C CN B011421495 A CNB011421495 A CN B011421495A CN 01142149 A CN01142149 A CN 01142149A CN 1233645 C CN1233645 C CN 1233645C
- Authority
- CN
- China
- Prior art keywords
- compound
- methyl
- buprenorphine
- oripavine
- oripavine derivative
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- ZKLXUUYLEHCAMF-UUWFMWQGSA-N Oripavine Chemical class C([C@@H](N(CC1)C)C2=CC=C3OC)C4=CC=C(O)C5=C4[C@@]21[C@H]3O5 ZKLXUUYLEHCAMF-UUWFMWQGSA-N 0.000 title claims abstract description 22
- 150000001875 compounds Chemical class 0.000 claims abstract description 63
- 239000003814 drug Substances 0.000 claims abstract description 19
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 14
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Divinylene sulfide Natural products C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims abstract description 5
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims abstract description 4
- 150000003839 salts Chemical class 0.000 claims abstract description 4
- 229930192474 thiophene Natural products 0.000 claims abstract description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 3
- 238000002360 preparation method Methods 0.000 claims description 8
- 239000000730 antalgic agent Substances 0.000 claims description 4
- 208000026251 Opioid-Related disease Diseases 0.000 claims description 2
- 201000005040 opiate dependence Diseases 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000000202 analgesic effect Effects 0.000 abstract description 11
- 229940079593 drug Drugs 0.000 abstract description 11
- 206010013663 drug dependence Diseases 0.000 abstract description 8
- 229940051808 oripavine derivative analgesics Drugs 0.000 abstract description 2
- 208000004224 Opium Dependence Diseases 0.000 abstract 1
- 125000004981 cycloalkylmethyl group Chemical group 0.000 abstract 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 abstract 1
- 231100000252 nontoxic Toxicity 0.000 abstract 1
- 230000003000 nontoxic effect Effects 0.000 abstract 1
- 229960001736 buprenorphine Drugs 0.000 description 40
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 36
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 30
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 27
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 23
- 238000006243 chemical reaction Methods 0.000 description 21
- 230000036592 analgesia Effects 0.000 description 20
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 19
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 18
- 238000002474 experimental method Methods 0.000 description 18
- FQXXSQDCDRQNQE-VMDGZTHMSA-N thebaine Chemical compound C([C@@H](N(CC1)C)C2=CC=C3OC)C4=CC=C(OC)C5=C4[C@@]21[C@H]3O5 FQXXSQDCDRQNQE-VMDGZTHMSA-N 0.000 description 18
- 241000700159 Rattus Species 0.000 description 17
- 229910052799 carbon Inorganic materials 0.000 description 17
- 241000699666 Mus <mouse, genus> Species 0.000 description 16
- 238000000034 method Methods 0.000 description 16
- 239000000243 solution Substances 0.000 description 16
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- 229960005181 morphine Drugs 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 11
- 238000001035 drying Methods 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- -1 ethylene methacrylic ketone Chemical class 0.000 description 11
- 239000007787 solid Substances 0.000 description 11
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 10
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 10
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 9
- FQXXSQDCDRQNQE-UHFFFAOYSA-N markiertes Thebain Natural products COC1=CC=C2C(N(CC3)C)CC4=CC=C(OC)C5=C4C23C1O5 FQXXSQDCDRQNQE-UHFFFAOYSA-N 0.000 description 9
- 229930003945 thebaine Natural products 0.000 description 9
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 8
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 238000000605 extraction Methods 0.000 description 8
- 230000036407 pain Effects 0.000 description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 7
- ZKLXUUYLEHCAMF-UHFFFAOYSA-N Oripavine Natural products COC1=CC=C2C(N(CC3)C)CC4=CC=C(O)C5=C4C23C1O5 ZKLXUUYLEHCAMF-UHFFFAOYSA-N 0.000 description 7
- 229910001873 dinitrogen Inorganic materials 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- 241000282560 Macaca mulatta Species 0.000 description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
- 102000003840 Opioid Receptors Human genes 0.000 description 6
- 108090000137 Opioid Receptors Proteins 0.000 description 6
- 229960004127 naloxone Drugs 0.000 description 6
- 239000002504 physiological saline solution Substances 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 230000006399 behavior Effects 0.000 description 5
- 229960000935 dehydrated alcohol Drugs 0.000 description 5
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 5
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 208000011117 substance-related disease Diseases 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- GZUXJHMPEANEGY-UHFFFAOYSA-N bromomethane Chemical compound BrC GZUXJHMPEANEGY-UHFFFAOYSA-N 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 239000004031 partial agonist Substances 0.000 description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 230000004580 weight loss Effects 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 235000019270 ammonium chloride Nutrition 0.000 description 3
- 238000013016 damping Methods 0.000 description 3
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 230000003236 psychic effect Effects 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 229960001866 silicon dioxide Drugs 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- 238000010254 subcutaneous injection Methods 0.000 description 3
- 239000007929 subcutaneous injection Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000012549 training Methods 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 description 2
- 206010013754 Drug withdrawal syndrome Diseases 0.000 description 2
- 239000005977 Ethylene Substances 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 2
- 238000007259 addition reaction Methods 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 230000001335 demethylating effect Effects 0.000 description 2
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 description 2
- 150000002431 hydrogen Chemical class 0.000 description 2
- 238000005984 hydrogenation reaction Methods 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- UOTMYNBWXDUBNX-UHFFFAOYSA-N 1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxyisoquinolin-2-ium;chloride Chemical compound Cl.C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 UOTMYNBWXDUBNX-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- PAWNEPWFHAMWEZ-UHFFFAOYSA-N C1C(ClC)CCCC1 Chemical compound C1C(ClC)CCCC1 PAWNEPWFHAMWEZ-UHFFFAOYSA-N 0.000 description 1
- XUCAHJHGSSPZLJ-UHFFFAOYSA-N CC1CCCC1.[Cl] Chemical compound CC1CCCC1.[Cl] XUCAHJHGSSPZLJ-UHFFFAOYSA-N 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- 206010052804 Drug tolerance Diseases 0.000 description 1
- 239000007818 Grignard reagent Substances 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- MASVCBBIUQRUKL-UHFFFAOYSA-N POPOP Chemical compound C=1N=C(C=2C=CC(=CC=2)C=2OC(=CN=2)C=2C=CC=CC=2)OC=1C1=CC=CC=C1 MASVCBBIUQRUKL-UHFFFAOYSA-N 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 206010048232 Yawning Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- BHELZAPQIKSEDF-UHFFFAOYSA-N allyl bromide Chemical compound BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 238000006757 chemical reactions by type Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000006957 competitive inhibition Effects 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 150000004795 grignard reagents Chemical class 0.000 description 1
- 230000026781 habituation Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000031868 operant conditioning Effects 0.000 description 1
- 229940124636 opioid drug Drugs 0.000 description 1
- 229960003207 papaverine hydrochloride Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 210000005245 right atrium Anatomy 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
- C07D489/09—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems
- C07D489/10—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems with a bridge between positions 6 and 14
- C07D489/12—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems with a bridge between positions 6 and 14 the bridge containing only two carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Priority Applications (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB011421495A CN1233645C (zh) | 2001-09-14 | 2001-09-14 | 新的东罂粟碱衍生物及其医药用途 |
| US10/489,656 US7119100B2 (en) | 2001-09-14 | 2002-09-13 | Oripavine derivatives and their uses as pharmaceuticals |
| DE60225827T DE60225827D1 (de) | 2001-09-14 | 2002-09-13 | Neue oripavinderivate und deren verwendungen als arzneimittel |
| MXPA04002422A MXPA04002422A (es) | 2001-09-14 | 2002-09-13 | Nuevos derivados de oripavina y su uso como farmaceuticos. |
| AT02764501T ATE390428T1 (de) | 2001-09-14 | 2002-09-13 | Neue oripavinderivate und deren verwendungen als arzneimittel |
| EP02764501A EP1439179B1 (en) | 2001-09-14 | 2002-09-13 | New oripavine derivatives and their uses as medicines |
| PCT/CN2002/000642 WO2003024972A1 (en) | 2001-09-14 | 2002-09-13 | New oripavine derivatives and their uses as medicines |
| JP2003528819A JP4532109B2 (ja) | 2001-09-14 | 2002-09-13 | 新規オリパビン誘導体および医薬としてのその使用 |
| ZA2004/02733A ZA200402733B (en) | 2001-09-14 | 2004-04-07 | New oripavine derivatives and their uses as medicines |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB011421495A CN1233645C (zh) | 2001-09-14 | 2001-09-14 | 新的东罂粟碱衍生物及其医药用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1408714A CN1408714A (zh) | 2003-04-09 |
| CN1233645C true CN1233645C (zh) | 2005-12-28 |
Family
ID=4676657
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB011421495A Expired - Lifetime CN1233645C (zh) | 2001-09-14 | 2001-09-14 | 新的东罂粟碱衍生物及其医药用途 |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP1439179B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP4532109B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN1233645C (cg-RX-API-DMAC7.html) |
| AT (1) | ATE390428T1 (cg-RX-API-DMAC7.html) |
| DE (1) | DE60225827D1 (cg-RX-API-DMAC7.html) |
| MX (1) | MXPA04002422A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2003024972A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA200402733B (cg-RX-API-DMAC7.html) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1939920B (zh) * | 2005-09-29 | 2011-08-31 | 中国人民解放军军事医学科学院毒物药物研究所 | 东罂粟碱类化合物及其医药用途 |
| JP2009522357A (ja) * | 2006-01-05 | 2009-06-11 | マリンクロッド・インコーポレイテッド | ブプレノルフィンのための出発物質としてのオリパビンの使用 |
| US20080125592A1 (en) | 2006-10-17 | 2008-05-29 | Penick Corporation | Process for preparing oxymorphone, naltrexone, and buprenorphine |
| CA2674915C (en) | 2006-10-17 | 2015-06-30 | Penick Corporation | Process for preparing oxymorphone |
| JP2011516464A (ja) * | 2008-03-31 | 2011-05-26 | サン・ファーマシューティカル・インダストリーズ・リミテッド | モルフィナン類似体の改良された調製方法 |
| CA2738628C (en) | 2008-09-30 | 2017-07-04 | Mallinckrodt Inc. | Processes for the selective amination of ketomorphinans |
| AU2009300387B2 (en) | 2008-09-30 | 2014-07-10 | SpecGx LLC | Processes for the synthesis of opiate alkaloids with reduced impurity formation |
| ES2529057T3 (es) | 2008-09-30 | 2015-02-16 | Mallinckrodt Inc. | Procedimientos para la hidrogenación de derivados de alcaloides opiáceos |
| AU2009300386B2 (en) | 2008-09-30 | 2015-07-02 | SpecGx LLC | Processes for the alkylation of norbuprenorphine with reduced impurity formation |
| WO2010039220A1 (en) * | 2008-09-30 | 2010-04-08 | Mallinckrodt Inc. | Processes for the production of buprenorphine with reduced impurity formation |
| WO2010039221A1 (en) * | 2008-09-30 | 2010-04-08 | Mallinckrodt Inc. | Recycling process for increasing the yield of a grignard reaction in the preparation of opiate alkaloid derivatives |
| TWI630208B (zh) | 2008-12-08 | 2018-07-21 | 歐陸斯迪公司 | 二氫羥戊甲嗎啡 |
| CN102462680B (zh) * | 2010-11-04 | 2016-08-03 | 中国人民解放军军事医学科学院毒物药物研究所 | 噻吩诺啡的长效缓释微球及其组合物和制备方法 |
| CN102382118A (zh) * | 2011-05-23 | 2012-03-21 | 浙江仙琚制药股份有限公司 | 一种7ɑ-乙酰基-6,14-乙基桥四氢蒂巴因的制备方法 |
| GB201309654D0 (en) | 2013-05-30 | 2013-07-17 | Euro Celtique Sa | Method |
| EP3023427A1 (en) | 2014-11-19 | 2016-05-25 | Siegfried AG | Improved method of manufacturing buprenorphine and analogues thereof from oripavine |
| EP3067357A1 (en) | 2015-03-11 | 2016-09-14 | Siegfried AG | Method of manufacturing stereoisomers of buprenorphine and analogues thereof |
| GB2550566A (en) | 2016-05-19 | 2017-11-29 | Chapelglade Ltd | Mattress evaluation system and method |
| CN108530452B (zh) * | 2017-03-01 | 2023-02-03 | 泰州华元医药科技有限公司 | 高效抗成瘾药物 |
| EP4613751A1 (en) | 2024-03-07 | 2025-09-10 | Siegfried AG | Method of making chemical compounds useful for the synthesis of buprenorphine |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB925723A (en) * | 1960-09-05 | 1963-05-08 | J F Macfarlan & Company Ltd | Novel thebaine derivatives |
| US3474101A (en) * | 1960-09-05 | 1969-10-21 | Reckitt & Sons Ltd | Thebaine and oripavine derivatives |
| DE2230154A1 (de) * | 1972-06-21 | 1974-01-17 | Boehringer Sohn Ingelheim | N-(heteroaryl-methyl)-6,14-endoaetheno7alpha-hydroxyalkyl-tetrahydro-nororipavine und -thebaine, deren hydrierungsprodukte und saeureadditionssalze sowie verfahren zu deren herstellung |
| KR100204659B1 (ko) * | 1996-05-28 | 1999-06-15 | 강재헌 | 신규한 부프레노핀계 진통제용 화합물 |
-
2001
- 2001-09-14 CN CNB011421495A patent/CN1233645C/zh not_active Expired - Lifetime
-
2002
- 2002-09-13 MX MXPA04002422A patent/MXPA04002422A/es active IP Right Grant
- 2002-09-13 JP JP2003528819A patent/JP4532109B2/ja not_active Expired - Lifetime
- 2002-09-13 DE DE60225827T patent/DE60225827D1/de not_active Expired - Lifetime
- 2002-09-13 WO PCT/CN2002/000642 patent/WO2003024972A1/zh not_active Ceased
- 2002-09-13 EP EP02764501A patent/EP1439179B1/en not_active Expired - Lifetime
- 2002-09-13 AT AT02764501T patent/ATE390428T1/de not_active IP Right Cessation
-
2004
- 2004-04-07 ZA ZA2004/02733A patent/ZA200402733B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2003024972A8 (en) | 2004-06-17 |
| EP1439179B1 (en) | 2008-03-26 |
| EP1439179A4 (en) | 2005-10-12 |
| EP1439179A1 (en) | 2004-07-21 |
| JP2005506985A (ja) | 2005-03-10 |
| MXPA04002422A (es) | 2005-04-11 |
| JP4532109B2 (ja) | 2010-08-25 |
| ZA200402733B (en) | 2005-02-23 |
| DE60225827D1 (de) | 2008-05-08 |
| ATE390428T1 (de) | 2008-04-15 |
| CN1408714A (zh) | 2003-04-09 |
| WO2003024972A1 (en) | 2003-03-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1233645C (zh) | 新的东罂粟碱衍生物及其医药用途 | |
| JP3313361B2 (ja) | 抗咳剤としてのエンドエテノ／エンドエタノ―エポキシモルヒナン誘導体の（＋）―アイソマー | |
| US11130765B2 (en) | Opioid ketal compounds and uses thereof | |
| JP6309957B2 (ja) | ケタミン誘導体 | |
| CN1087340A (zh) | 哌啶衍生物及其制备和在治疗学上的应用 | |
| CA2238524A1 (en) | Tricyclic ibogaine analogs, their preparation and their use in treating substance abuse | |
| CN1220667A (zh) | 吗啡烷衍生物及医药用途 | |
| CA2221744A1 (en) | Alpha 1a adrenergic receptor antagonists | |
| DK1758452T3 (en) | METABOLIC STABLE ANALGETICS AND Painkillers | |
| JP2009520033A (ja) | 物質乱用および依存症を治療するためのベンゾ縮合複素環スルファミド誘導体の使用 | |
| JP2014073964A (ja) | モルヒナン誘導体 | |
| CN1403445A (zh) | N－取代的氮杂环化合物 | |
| KR101285645B1 (ko) | 진통제 | |
| CN1085979C (zh) | 麻药型镇痛剂依赖性/抗性形成抑制剂 | |
| CN1665820A (zh) | 用于预防恶心和呕吐的治疗剂或预防剂 | |
| CN1915993A (zh) | 海南狗牙花吲哚类生物碱及其在制备戒毒药物中的用途 | |
| JPS6379857A (ja) | 新規化合物、その製法及びそれを含む医薬組成物 | |
| CN1049577C (zh) | 那布扶林镇痛剂的长效前体药物及其制备方法 | |
| US7119100B2 (en) | Oripavine derivatives and their uses as pharmaceuticals | |
| WO2014198164A1 (zh) | 顺式苄基异喹啉类化合物、其制备方法及其用途 | |
| Casy et al. | Chemistry and Pharmacology of 4-Alkoxy-piperidines Related to Reversed Esters of Pethidine | |
| Abdel-Rahman et al. | Synthesis and Pharmacology of 6-Methylenedihydrodesoxymorphine1 | |
| KR810001913B1 (ko) | 3-페녹시 n-치환된 모르피난 유도체의 제조방법 | |
| KR20230116709A (ko) | 정신질환의 예방 또는 치료용 약제학적 조성물 | |
| JPWO2001014382A1 (ja) | モルヒナン４級アンモニウム塩誘導体を有効成分とする鎮痛薬 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CX01 | Expiry of patent term | ||
| CX01 | Expiry of patent term |
Granted publication date: 20051228 |